Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer’s disease: randomized, placebo-controlled, double-blind, phase I clinical trial

Manuscript Number: 

21-5511R1

Author(s): 
Kevin Church, Philippe Danjou, Suzanne B. Hendrix, Xue Hua, Philippe L’Hostis, Hans J. Moebius, Geoffrey Viardot, William Walker

Disclosures

Kevin Church

  • Equity:
    Equity compensation from Athira Pharma

Philippe Danjou

  • Consulting Fees:
    consulting fees from Biotrial,Syndesi Bionomics,Neurogastx, Asceneuron, Innoved Therapeutics
    Patents/Royalties
    Patent author for Wyeth Ayerst (Pfizer)

Suzanne B. Hendrix

  • Consulting Fees:
    Pentara consults on dozens of Alzheimer's Disease programs and was contracted for statistical support on this study.

Xue Hua

  • Equity:
    Xue Hua is an Athira employee with salary and equity compensation.
    Sponsors:
    Vice President of Clinical Development, Research, Athira Pharma, Inc.

Philippe L’Hostis

  • Nothing to Disclose

Hans J. Moebius

  • Equity:
    Athira employee NSOs with annual refresher and RSUs
    Sponsors:
    full time employee as CMO

Geoffrey Viardot

  • Nothing to Disclose

William Walker

  • Equity:
    I am an employee at Athira Pharma, Inc. with salary and non-material equity compensation.
    Sponsors:
    I am an employee at Athira Pharma, Inc.